Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19
Abstract Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospit...
Saved in:
| Main Authors: | Mark Berry, Amanda M. Kong, Roger Paredes, Julie Paone, Rohan Shah, Rebecca Taylor, Essy Mozaffari, Rikisha Gupta, Robert L. Gottlieb, Lourdes Mateu, Mazin Abdelghany, Jason D. Goldman, Anand P. Chokkalingam |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-06052-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
by: I. Gentile, et al.
Published: (2025-12-01) -
Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database
by: Manami Yoshida, et al.
Published: (2025-06-01) -
Case report: Persistent COVID-19 in a patient with B cell lymphoma refractory to antiviral treatment due to resistance to Remdesivir
by: Luiz Eduardo Ceccon Calil de Assumpção, et al.
Published: (2025-01-01) -
Remdesivir and hospitalization outcomes in patients with COVID -19 in the period of SARS-CoV-2 Delta circulation
by: D. V. Litvinchuk, et al.
Published: (2025-06-01) -
Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19: retrospective observational cohort study
by: Nithish Sattoju, et al.
Published: (2023-07-01)